GENETIC SIGNATURES LIMITED (GSS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

GSS - GENETIC SIGNATURES LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.06
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.717

21 Nov
2024

0.017

OPEN

$0.70

2.43%

HIGH

$0.72

18,998

LOW

$0.70

TARGET
$1.10 53.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
GSS: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 10.8 - 4.8 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-10.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx9.8 M
Book Value Per Share xxxxxxxxxxxxxxx28.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-10.1 M
Net Profit Margin xxxxxxxxxxxxxxx-182.90 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-34.34 %
Return on Invested Capital xxxxxxxxxxxxxxx-34.07 %
Return on Assets xxxxxxxxxxxxxxx-30.70 %
Return on Equity xxxxxxxxxxxxxxx-34.34 %
Return on Total Capital xxxxxxxxxxxxxxx-42.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-12.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx36 M
Price To Book Value xxxxxxxxxxxxxxx2.54

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx4.8 M
Capex % of Sales xxxxxxxxxxxxxxx49.06 %
Cost of Goods Sold xxxxxxxxxxxxxxx26 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

01/11/2024

1

Speculative Buy

$1.10

53.42%

Genetic Signatures reported a "strong" 1Q25 result, notes Bell Potter, with sales advancing 194% year-on-year and up 4% on the quarter.

Australian sales, excluding covid-specfic tests, were in line following the resolution of FluB test issues. 

Bell Potter believes the rollout in the US of the first diagnostic test is "critical" to the investment case for the company. No US sales have been reported yet, the analyst notes, with expectations of sales in 1H25.

The Speculative Buy rating and $1.10 target are maintained. No change to EPS forecasts.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.80 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.34 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Taylor Collison

23/05/2024

2

Speculative Outperform

$2.21

208.23%

In a potentially transformational milestone, Taylor Collison points out the final stage is approaching for FDA review of Genetic Signatures' 510(k) application.

The company is seeking clearance to market its EasyScreen gastrointestinal parasite (GIP) test kit in the US. If approved, the analyst is expecting a rapid take-up as the test meets an unmet need, and reimbursement at US$263/test is already in place.

While the broker is expecting a decision before the end of May, there is a moderate risk the FDA review could continue into June.

The Speculative Outperform rating is maintained. Target $2.21.

FORECAST
Taylor Collison forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.40 cents.
Access Extra Coverage Research History >

GSS STOCK CHART

FNArena News on GSS

1
FNArena Corporate Results Monitor – 06-09-2024

Sep 06 2024 - Australia
2
Australian Broker Call *Extra* Edition – May 23, 2024

May 23 2024 - Daily Market Reports
3
FNArena Corporate Results Monitor – 26-02-2024

Feb 26 2024 - Australia
4
Australian Broker Call *Extra* Edition – Sep 25, 2023

Sep 25 2023 - Daily Market Reports
5
Weekly Ratings, Targets, Forecast Changes – 22-09-23

Sep 25 2023 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps